Weekly Digest – September 2026 Weekly Digest – September 2026 16 September 2026: Enhertu and Datroway approved in Japan for two new 1L indications in metastatic Breast cancer Daiichi Sankyo announced that Enhertu and Datroway have been approved in Japan […]
Weekly Digest – October 2025 Weekly Digest – October 2025 23 October 2025: Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma The US FDA has approved Blenrep (Belantamab mafodotin) in combination with bortezomib and dexamethasone […]
Weekly Digest – October 2025 Weekly Digest – October 2025 17 October 2025: Core product Trastuzumab botidotin approved for marketing by the NMPA for 2L+ HER2+ breast cancer Sichuan Kelun-Biotech’s core product trastuzumab botidotin (A166) received marketing approval from China’s […]
